(Q35110895)

6 August 2017

1 reference

title

Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases (English)

1 reference

6 August 2017

0 references

Jeffrey I. Cohen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12704588

25 December 2023

language of work or name

1 reference

1 April 2003

1 reference

6 August 2017

Seminars in Hematology

1 reference

6 August 2017

40

1 reference

6 August 2017

2

1 reference

6 August 2017

116-123

1 reference

Epstein-Barr virus in the bone marrow of patients with aplastic anemia

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Large clonal expansions of CD8+ T cells in acute infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

SAP is required for generating long-term humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

T- and B-Cells in Peripheral Blood during Infectious Mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Treatment of Epstein-Barr virus-associated malignancies with specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Immunotherapeutic strategies for EBV-associated malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Burkitt lymphoma in the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

X-linked lymphoproliferative disease: a progressive immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Disseminated intravascular coagulation and hepatic necrosis. Complications of infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Acute Epstein-Barr virus infection complicated by severe thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Antineutrophil antibodies in infectious mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

X-linked lymphoproliferative disease: twenty-five years after the discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Acyclovir for treatment of infectious mononucleosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Activation of Suppressor T Cells during Epstein-Barr-Virus-Induced Infectious Mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

“Decisions, decisions ...”: β-catenin–mediated activation of TCF-1 and Lef-1 influences the fate of developing T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

Epstein-Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970003-1

7 January 2021

10.1016/S0037-1963(03)70003-1

Identifiers

DOI

1 reference

6 August 2017

10.1053/SHEM.2003.50018

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12704588

25 December 2023

1 reference